Novogene Co. Ltd. (688315)
Shanghai Stock Exchange · China · prices in CNY · close of 23 Oct 2026
Key indicators
| Last close | CNY 19.35 |
|---|---|
| 52-week range | 11.46 – 23.43 |
| Return, 1 month / 3 months | −0.2% / +57.3% |
| Return, 1 year / 3 years | +31.5% / −5.5% |
| Trend | Uptrend |
| RSI (14) | 55 |
| Volatility (1 year) | 54.3% |
| Worst drawdown (1 year) | -29.6% |
| Average daily value traded | 271.45M CNY |
| Dividend yield | 0.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Novogene is a genomics company based in Beijing that provides gene sequencing and bioinformatics services to research and healthcare customers. Its work supports scientists at universities, hospitals, research institutes and pharmaceutical companies who study genetics, disease and drug development. The company offers sequencing across several platforms along with data analysis and related laboratory services, helping customers turn biological samples into interpretable genetic information for their research projects.
Novogene Co. Ltd. trades under the code 688315 on the Shanghai Stock Exchange in China, with its price quoted in Chinese yuan (CNY). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Novogene Co. Ltd. (688315) trades on the Shanghai Stock Exchange in China. It last closed at CNY 19.35 on 23 October 2026.
Its price-based Market X-Ray is 77 out of 100 (a strong price profile), ranking 123 of 2,278 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 31.5% and over the last three months it rose 57.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shanghai Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 96 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 31.5% | ||
| From 52-week high | -12.1% | ||
| Momentum | 93 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 57.3% | ||
| 6-month return | 36.8% | ||
| 12-month return, skipping the last month | 31.7% | ||
| Stability (higher is calmer) | 58 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 54.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.6% | ||
| Liquidity | 70 · Strong | Trades actively. | |
| Average daily value traded | 271.45M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | 41 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.2% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +8.5% |
|---|---|
| 1 month | −0.2% |
| 3 months | +57.3% |
| 6 months | +36.8% |
| 1 year | +31.5% |
| 3 years | −5.5% |
| 5 years | −50.9% |
Signals
| 50-day / 200-day average | 16.63 / 14.72 |
|---|---|
| Golden / death cross (60 days) | Golden, 18 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.02 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 10 Jun 2026 | CNY 0.0450 |
| 10 Jun 2025 | CNY 0.0500 |
| 31 May 2024 | CNY 0.0475 |
| 18 May 2023 | CNY 0.0470 |
| 6 Jul 2022 | CNY 0.0600 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shanghai Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.